ARCHIVES

FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion

This article is from The Cancer Letter archive.

Vol. 18 No. 01 | January 3, 1992

Download PDF Visit The Full Archive

Related Articles

Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy

September 27, 2013

DCE Board Approves concept For New Studies On Black, White Differences In Cancer Rates

July 13, 1984

‘Rush To Downsize’ Is A Danger To NCI, Broder Warns In A Farewell Address

January 13, 1995

No Cancer Letter For Two Weeks

August 10, 1990

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

With workload Up, Oncology Division To Add More Staff

August 2, 1996